Mesenchymal stem cells (MSCs) are multipotent cells that can differentiate into a variety of cell types, including osteoblasts, chondrocytes, myocytes, adipocytes, and potentially other cell types. For years, it has been clear that MSCs are a leading type of stem cell being investigated for therapeutic applications, because they have the potential to treat a wide range of acute and degenerative diseases.
In addition to secreting factors that can stimulate tissue repair, MSCs can substantially alter their microenvironment, exerting effects that are both anti-inflammatory and anti-fibrotic. MSCs are also advantageous over other stem cells types, because they avoid the ethical issues that surround embryonic stem cell research and appear to be immuno-privileged.
Importantly, MSCs also well-suited for use in the exponential growth area of 3D printing, because of their unusual capacity to form structural tissues.
Recently released, “Mesenchymal Stem Cells – Advances & Applications” is a global strategic report that describes the current status of MSC research, ongoing clinical trials involving MSCs, late stage MSC clinical trials, and possible uses of MSCs in cell therapy. Because MSCs are a sub-segment of the broader cell therapy (CT) and regenerative medicine (RM) markets, it also gives an overview of the regenerative medicine industry and overall cell therapy industry.
It also explores recent advances in MSC products and technologies, identifies research priorities by market segment, and assesses 35 leading competitors within the MSC marketplace. For pharmaceutical companies, it reveals how advances in MSC research can reveal potential new drug targets, improve methods of drug delivery, and provide personalized treatment strategies.
For more information on the growing market for MSCs, please click on:
The main objectives of the report are to consider the following:
– Current status of global regenerative medicine (RM) industry in the utilization of stem cells in general and MSCs in particular
– Current status of global cell therapy (CT) industry, the application of cell therapy in various disease indications, and the total number of clinical trials involving the different types of stem cells
– Current status of MSCs in clinical trials, the dominance of MSCs in the ongoing clinical trials involving stem cells, the various applications of MSCs in different disease indications, and the number of clinical trials involving MSCs for different disease types
– The number of companies involved in the development of MSCs, the clinical trials sponsored by major companies, and their ongoing search for MSCs-based cell therapy products
– Analysis of traditional market metrics (grant rates, clinical trial rates, patent rates, scientific publication rates, and more) and new social analytics (metrics from social media platforms, Google Search, Google Trends, Google Adwords, and more)
Key questions answered in the report are:
– How many companies are currently supporting the regenerative medicine (RM) industry?
– What is the current regional breakdown of RM industry?
– How many RM products have been approved?
– What are the types of diseases are currently being pursued by RM companies?
– What are the major financial events, partnerships, and acquisitions in RM sector?
– How do the large pharma companies perceive the value and long-term prospects of RM and cell therapy (CT)?
– What are the major anticipated RM clinical events in 2015-16?
– What are the major therapeutic opportunities for the big pharma in RM and CT?
– How many CT product candidates have reached the Phase III stage and what are they?
– What are the CT product candidates being developed for cardiovascular diseases, central nervous system, wounds, spine and orthopedics, diabetes and autoimmune diseases?
– What are the major commercially available CT products?
– What is the total number of CT clinical trials at the global level?
– What are the major cell types used in CT clinical trials?
– What are the major indications addressed by CT clinical trials?
– What are the major CT clinical trials that have reached Phase III?
– How many CT clinical trials failed in the past year and what are they?
– What are the contributions of MSCs to the cell therapy industry?
– What are the biological properties of MSCs?
– What do MSCs get differentiated into?
– What bioactive molecules do the MSCs secrete?
– What are the immunomodulatory functions of MSCs?
– What are the factors impacting the acquisition of MSCs?
– What are the various sources of MSCs?
– What are the ongoing clinical trials using bone marrow-derived MSCs (BMMSCs) for kidney diseases?
– What are the major clinical trials focusing on diabetes using BMMSCs?
– What are the major clinical trials involving BMMSCs for cardiovascular diseases?
– What are the major clinical trials focusing on liver diseases by BMMSCs?
– What are the brain-related diseases addressed by clinical trials using BMMSCs?
– How many clinical trials are conducted for intestinal diseases using MSCs?
– What are the details of clinical trials conducted for musculoskeletal diseases using MSCs?
– Number of clinical trials using MSCs derived from Wharton’s jelly for various diseases?
– What are the disease indications addressed by umbilical cord blood-derived MSCs (UCBMSCs) in current clinical trials?
– What is the current number of clinical trials using MSCs?
– How many major clinical trials using MSCs have reached the Phase III?
– What are the MSCs-based cell therapy products available in the market?
– What is the current size of the MSC marketplace?
– What are 5-year projections the MSC marketplace?
For more information please click on:
1. Executive Summary
2. Report Overview
2.1 Target Demographic
2.2 Key Findings
2.3 Statement of the Report
3. Research Methodology
3.1 Input Sources
3.2 Research & Analysis Methodologies
3.3 Criteria for Identiyfing MSC Market Leaders
4. Mesenchymal Stem Cell (MSC Definitions & Nomenclature)
4.2. Alternative Nomenclature
5. MSC Criteria & Characteristics
5.1 Discovery – Key Dates in the Discovery of Mesenchymal Stem Cells
5.2 Physical Assessment
5.3 Functional Attributes
5.4. Benefits of MSCs Relative to Other Stem Cells
6. MSC Isolation Sources
6.1 Adult Sources
6.2 Fetal Sources
7. Commercial Interest In MSC
7.1 Cell Types Derived from MSCs
7.2 Therapeutic Potential of MSCs
8. Introduction To Regenerative Medicine (RM Industry)
8.1 Regenerative Medicine (RM and Advanced Therapies Industry: A Brief Overview)
8.2 Global Breakdown of Regenerative Medicine (RM Industry by Region)
8.3 Breakdown of Global RM Companies by Type
8.4 Number of RM Clinical Trials by Phase of Development
8.5 Major Financial Events in the RM Industry
8.6 Major Partnerships and Acquisitions in RM Industry
8.7 Major Regulatory Milestones in RM Industry
8.8 Major Pharma and Biotech Companies Active in Advanced Therapies
8.9 Major Corporate Partnerships in RM Industry
8.10 Anticipated Major RM Clinical Events
9. Introduction To The Stem Cell Therapy Industry
9.1 Types of Stem Cells Used in Cell Therapy
9.2 Types of Stem Cells Used in Cell Therapy, sorted by Differentiation Potential
10. Cell Therapy (CT Products: Successes And Failures)
10.1 Cell Therapy Product Candidates in Late-Stage Clinical Development
10.2 Cell Therapy Products Being Developed for Cardiovascular Indication
10.3 Cell Therapy Products Being Developed for Other Indications
10.4 Major Commercially Available Cell Therapy Products
10.5 Cell Therapy Products Approved in South Korea
10.6 Major Cell Therapies in Phase III
10.7 Clinical Trial Failures in Cell Therapy
11. The Market For Mesenchymal Stem Cell Therapies
11.1 Market Potential – All Stem Cell Types
11.2. Market Potential – Mesenchymal Stem Cells
11.3 Global Market for Stem Cells by Disease Indication
12. Research And Therapeutic Applications Of MSCs
12.1 Basic Research Applications
12.2 Cell Transplantation for Site-Specific Repair
12.3 Directed Differentiation of Mesenchymal Stem Cells
12.4 Drug Delivery Applications: Engineered MSCs as Carriers of Anti-Cancer Drugs
12.5 Drug Screening
12.6 Gene Transfer Studies
12.7 MSC-Mediated Inhibition of Immune Effector Cells
12.8 Supporting Hematopoietic Cell Applications
12.9 Use of 3-D Scaffolds for Tissue Engineering
12.10 Topical Therapy and Use of MSCs in Wound Healing
13. MSC Product Development Variables – Attributes & Acquisition
13.1 Biological Properties of MSCs Contributing to Therapeutic Effects
13.2 Factors Impacting MSCs Acquisition
13.3 Major Clinical Sources of MSCs
14. Clinical Applications Of Mesenchymal Stem Cells
14.1 Bone Marrow-Derived Mesenchymal Stem Cells (BMMSCs)
14.2 Adipose-Derived Mesenchymal Stem Cells (ADSCs)
14.3 Mesenchymal Stem Cells (MSCs Derived from Wharton’s Jelly
14.4 Umbilical Cord Blood-Derived MSCs (UCBMSCs)
14.5 Dominance of MSCs in Cell Therapy Clinical Trials
15. Major Diseases Addressed By MSCs In Current Clinical Trials
15.1 MSCs for Treating Liver Diseases
15.2 MSCs for Neurodegenerative Diseases
15.3 Clinical Trials Using MSCs for Autoimmune Diseases
15.4 Clinical Trials Using MSCs for Diabetes
15.5 MSCs for Cardiovascular Repair
15.6 MSCs for Musculoskeletal Diseases
15.7 MSCs in Neuron/Spinal Cord Diseases
15.8 MSC Infusion for GvHD
15.9 MSCs for Crohn’s Disease
15.10 MSCs in Wound Healing
15.11 Increasing Focus on Immunological Properties of MSCs
15.12 Selected MSCs Late-Stage Pipeline Cell Therapies
16. Market Opportunities For Biobanking Of Mesenchymal Stem Cells
16.1 Types of Mesenchymal Stem Cell Biobanking
16.2 Dental Stem Cell Banking (MSC Biobanking)
16.3 Umbilical Cord Tissue (MSC Biobanking)
16.4 Adipose-Derived MSCStorage
16.5 Other Types of MSCBio-Banking: Placental Tissue, Menstrual Stem Cells, Peripheral Blood Stem Cells, Bone Marrow Stem Cells, and More
17. Key Market Metrics Forf MSC
17.1 Global Breakdown of Mesenchymal Stem Cell Clinical Trials
17.2 Patent Analysis
17.3 Scientific Publication Analysis
17.4 Grant Rate Analysis
18. Social Analytics For Mesenchymal Stem Cells
18.1 Marketing Cost Analysis: Search Term “Mesenchymal Stem Cell”
18.2 MSC Articles Receiving Most Social Media Shares over Past 12 Months
18.3 Google Trend Data for MSCs
18.4 Twitter Hashtag Data
19. Selected Company Profiles
19.1 American Type Culture Collection Inc. (ATCC)
19.2 Anterogen Co., Ltd.
19.3 Apceth GmbH & Co. KG
19.4 BioCardia Inc.
19.5 BioRestorative Therapies Inc.
19.6 Bone Therapeutics SA
19.7 BrainStorm Cell Therapeutics Inc.
19.8 CellGenix Technologie Transfer GmbH
19.9 Celprogen Inc.
19.10 CellTherapies P/L
19.11 Cesca Therapeutics Inc.
19.12 Cyagen Biosciences Inc.
19.13 Cynata Therapeutics Ltd.
19.14 Cytori Therapeutics Inc.
19.15 Escape Therapeutics
19.17 Kite Pharma Inc.
19.18 Life Technologies Corporation
19.19 Lonza Group Ltd.
19.20 Medipost Co. Ltd.
19.21 Mesoblast Ltd.
19.22 NuVasive Inc.
19.23 Ocata Therapeutics Inc.
19.24 Organogenesis Inc.
19.25 Orthofix International N.V.
19.26 Osiris Therapeutics Inc.
19.27 Pluristem Therapeutics Inc.
19.29 Regeneus Ltd.
19.30 ScienCell Research Laboratories
19.31 STEMCELL Technologies Inc.
19.32 Stemedica Cell Technologies Inc.
19.33 Stempeutics Research Pvt. Ltd.
19.34 TiGenix N.V.
19.35 Vericel Corporation
List of Tables
List of Figures
– American Type Culture Collection Inc. (ATCC)
– Anterogen Co., Ltd.
– Apceth GmbH & Co. KG
– BioCardia Inc.
– BioRestorative Therapies Inc.
– Bone Therapeutics SA
– BrainStorm Cell Therapeutics Inc.
– CellGenix Technologie Transfer GmbH
– CellTherapies P/L
– Celprogen Inc.
– Cesca Therapeutics Inc.
– Cyagen Biosciences Inc.
– Cynata Therapeutics Ltd.
– Cytori Therapeutics Inc.
– Escape Therapeutics
– Kite Pharma Inc.
– Life Technologies Corporation
– Lonza Group Ltd.
– Medipost Co. Ltd.
– Mesoblast Ltd.
– NuVasive Inc.
– Ocata Therapeutics Inc.
– Organogenesis Inc.
– Orthofix International N.V.
– Osiris Therapeutics Inc.
– Pluristem Therapeutics Inc.
– Regeneus Ltd.
– STEMCELL Technologies Inc.
– ScienCell Research Laboratories
– Stemedica Cell Technologies Inc.
– Stempeutics Research Pvt. Ltd.
– TiGenix N.V.
– Vericel Corporation
For more information or to claim full access to this report, visit: